FDA-approved for the treatment of

Dermatomyositis
and Polymyositis

  • Polymyositis and dermatomyositis are potentially debilitating diseases characterized by muscle inflammation (myositis) with subsequent weakness1
  • Dermatomyositis also has skin manifestations2,3
  • Acthar is indicated for use during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis and polymyositis4
  • Based on clinical experience from a retrospective case series (n=5), Acthar has been shown to help improve manual muscle testing (MMT) scores.5* Learn more

*These results are based on a retrospective 5-patient case series and may not be fully representative of outcomes in the overall patient population. All 5 patients were on multiple therapies. The clinical outcomes may not be solely attributable to Acthar.

Mallinckrodt is committed to supporting patients.

  • Mallinckrodt offers access and reimbursement support through the Acthar Hub
  • The Hub works with physician offices to determine patient coverage and manage payer-specific requirements, including steps edits, prior authorizations, Letters of Medical Necessity, and appeals
  • It is common for an insurance company to require additional paperwork to determine coverage, and this process may take some time. The Hub is here to help every step of the way

IMPORTANT SAFETY INFORMATION

SEE More

Contraindications

  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
  • Acthar is contraindicated where congenital infections are suspected in infants
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

INDICATIONS

SEE More

H.P. Acthar® Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for:

  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
  • The treatment of symptomatic sarcoidosis
  • Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)